Myriad Genetics, Inc. (NASDAQ:MYGN)

lewanss (90.73) Submitted: 3/5/2007 12:06:07 PM : Start Price: $16.63 MYGN Score: +52.34

MEDICINE

utahsnowskier (73.03) Submitted: 2/5/2007 12:50:08 AM : Start Price: $17.55 MYGN Score: -48.57

Costly building expansion coupled with the negative earnings burning the cash pile away leads me to believe the price is mostly hype, unless you think all the drug canidates will be approved.

bethsheba (< 20) Submitted: 1/19/2007 7:55:02 PM : Start Price: $17.95 MYGN Score: +44.22

Although the pipeline of drug targets and ever increasing acceptance and utilization of their predictive genetic testing products continues to keep this stock in a steady position with modest yet consistent growth I feel certain that this stock will experience a substantial upswing as soon as the Phase III trials end and FDA approval comes in for the Alzheimers drug Flurbiprofen.

MarcHertz (< 20) Submitted: 11/17/2006 2:32:53 PM : Start Price: $14.87 MYGN Score: +71.44

Look to their alzheimers drug

BadMojowithstock (< 20) Submitted: 10/19/2006 11:34:58 AM : Start Price: $13.73 MYGN Score: +83.10

They are the only provider of gentic testing for breast cancer and breast cancer is epidemic.

Virtuehunter (60.57) Submitted: 10/16/2006 9:02:40 PM : Start Price: $13.20 MYGN Score: +90.57

Myriad has made some great progress with a number of drugs. Their Alzheimer medication has the potential to revolutionize how we treat this disease that affects millions.

sato1027 (48.42) Submitted: 10/3/2006 10:56:02 PM : Start Price: $12.27 MYGN Score: +102.62

Not focusing on Flurixan. Better candidate is Azixa for brain cancer.